Biologic therapy for posterior uveitis and panuveitis

Retina Today

Volumn , Issue APRIL, 2012, Pages 74-79

  Pasadhika, Sirichai ^a   Suhler, Eric B ^b   Cunningham, Emmett T ^c  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84863586183     PISSN: None     EISSN: 18250572     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Smith JA, Thompson DJ, Whitcup SM, et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum. 2005;53:18-23
2. Galor A, Perez VL, Hammel JP, Lowder CY. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology. 2006;113:2317-2323
3. Pato E, Munoz-Fernandez S, Francisco F, et al. Systematic review on the effectiveness of immunosuppressants and biological therapies in the treatment of autoimmune posterior uveitis. Semin Arthritis Rheum. 2011;40(4):314-323
4. Cunningham ET Jr., Wender JD. Practical approach to the use of corticosteroids in patients with uveitis. Can J Ophthalmol. 2010;45(4):352-358
5. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130:492-513
6. Lim L, Suhler EB, Smith JR. Biologic therapies for inflammatory eye disease. Clin Experiment Ophthalmol 2006;34:365-374
7. Cunningham ET, Zierhut M. TNF inhibitors for uveitis: balancing efficacy and safety. Ocul Immunol Inflamm 2010;18(6):421-423
8. Sfikakis PP, Theodossiadis PG, Katsiari CG, et al. Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet. 2001;358:295-296
9. Ohno S, Nakamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J Rheumatol. 2004;31:1362-1368
10. Suhler EB, Smith JR, Wertheim MS, et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol. 2005;123:903-912
11. Suhler EB, Smith JR, Giles TR, et al. Infliximab therapy for refractory uveitis: 2-year results of a prospective trial Arch Ophthalmol. 2009;127:819-822
12. Sfikakis PP, Kaklamanis PH, Elezoglou A, et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behcet disease. Ann Intern Med. 2004;140:404-406
13. Tabbara KF, Al-Hemidan AI. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behcet disease. Am J Ophthalmol. 2008;146: 845-850.e841
14. Kawaguchi T, Sugita S, Yamada Y, et al. Regression of optic disc neovascularization in patients with Behcet's uveoretinitis after infliximab therapy. J Ocul Pharmacol Ther. 2010;26(6):627-630
15. Ito T, Sonoda KH, Hijioka K, et al. Acquired resistance to infliximab against uveitis due to Behcet's disease after one year of administration. Jpn J Ophthalmol. 2010;54(5):502-504
16. Bawazeer A, Raffa LH, Nizamuddin SH. Clinical experience with adalimumab in the treatment of ocular Behcet disease. Ocul Immunol Inflamm. 2010;18(3):226-232
17. Takase K, Ohno S, Ideguchi H, et al. Successful switching to adalimumab in an infliximab-allergic patient with severe Behcet disease-related uveitis. Rheumatol Int. 2011;31(2):243-245
18. Mushtaq B, Saeed T, Situnayake RD, Murray PI. Adalimumab for sight-threatening uveitis in Behcet's disease Eye (Lond). 2007;21:824-825
19. Buggage RR, Levy-Clarke G, Sen HN, et al. A double-masked, randomized study to investigate the safetyand efficacy of daclizumab to treat the ocular complications related to Behcet's disease. Ocul Immunol Inflamm 2007;15:63-70
20. Ramos-Casals M, Brito-Zeron P, Munoz S, Soto MJ. A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Medicine (Baltimore). 2008;87:345-364
21. Baughman RP, Bradley DA, Lower EE. Infliximab in chronic ocular inflammation. Int J Clin Pharmacol Ther 2005;43:7-11
22. Clementine RR, Lyman J, Zakem J, et al. Tumor necrosis factor-alpha antagonist-induced sarcoidosis. J Clin Rheumatol. 16:274-279
23. Olivier A, Gilson B, Lafontaine S, et al. [Pulmonary and renal involvement in a TNFalpha antagonist druginduced sarcoidosis (published online ahead of print May 16, 2011)]. Rev Med Interne
24. Izzi S, Francesconi F, Visca P, et al. Pulmonary sarcoidosis in a patient with psoriatic arthritis during infliximab therapy. Dermatol Online J. 2010;16(5):16
25. Daien CI, Monnier A, Claudepierre P, et al. Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology (Oxford). 2009;48:883-886
26. Dhaille F, Viseux V, Caudron A, et al. Cutaneous sarcoidosis occurring during anti-TNF-alpha treatment: report of two cases. Dermatology. 2010;220(3):234-237
27. Metyas SK, Tadros RM, Arkfeld DG. Adalimumab-induced noncaseating granuloma in the bone marrow of a patient being treated for rheumatoid arthritis. Rheumatol Int. 2009;29:437-439
28. Takahashi H, Kaneta K, Honma M, et al. Sarcoidosis during infliximab therapy for Crohn's disease. J Dermatol 2010;37(5):471-474
29. Javot L, Tala S, Scala-Bertola J, et al. [Sarcoidosis and anti-TNF: a paradoxical class effect? Analysis of the French Pharmacovigilance system database and literature review.]. Therapie. 2011;66:149-154
30. Gupta SR, Phan IT, Suhler EB. Successful treatment of refractory sympathetic ophthalmia in a child with infliximab. Arch Ophthalmol. 2011;129(2):250-252
31. Niccoli L, Nannini C, Cassara E, et al. Efficacy of infliximab therapy in two patients with refractory Vogt- Koyanagi-Harada disease. Br J Ophthalmol. 2009;93:1553-1554
32. Wang Y, Gaudio PA. Infliximab therapy for 2 patients with Vogt-Koyanagi-Harada syndrome. Ocul Immunol Inflamm. 2008;16:167-171
33. Khalifa YM, Bailony MR, Acharya NR. Treatment of pediatric Vogt-Koyanagi-Harada syndrome with infliximab Ocul Immunol Inflamm. 2010;18(3):218-222
34. Diaz Llopis M, Amselem L, Romero FJ, et al. [Adalimumab therapy for Vogt-Koyanagi-Harada syndrome]. Arch Soc Esp Oftalmol. 2007;82:131-132
35. Sobrin L, Huang JJ, Christen W, et al. Daclizumab for treatment of birdshot chorioretinopathy. Arch Ophthalmol 2008;126:186-191
36. Seve P, Mennesson E, Grange JD, et al. Infliximab in serpiginous choroiditis. Acta Ophthalmol. 2010;88(8):e342-343
37. Cordero-Coma M, Benito MF, Hernandez AM, et al. Serpiginous choroiditis. Ophthalmology. 2008;115:1633, 1633 e1631-1632
38. Mackensen F, Becker MD, Wiehler U, et al. QuantiFERON TB-Gold-a new test strengthening long-suspected tuberculous involvement in serpiginous-like choroiditis. Am J Ophthalmol. 2008;146:761-766
39. Adan A, Sanmarti R, Bures A, Casaroli-Marano RP. Successful treatment with infliximab in a patient with diffuse subretinal fibrosis syndrome. Am J Ophthalmol. 2007;143:533-534
40. Markomichelakis NN, Theodossiadis PG, Pantelia E, et al. Infliximab for chronic cystoid macular edema associated with uveitis. Am J Ophthalmol. 2004;138:648-650
41. Deuter CM, Kotter I, Gunaydin I, et al. Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis. Br J Ophthalmol. 2009;93:906-913
42. Wang J, Ibrahim M, Turkcuoglu P, et al. Intercellular adhesion molecule inhibitors as potential therapy for refractory uveitic macular edema. Ocul Immunol Inflamm. 2010;18(5):395-398
43. Talamonti M, Teoli M, Botti E, et al. Patients with moderate to severe plaque psoriasis: one year after the European medicines agency recommendation of efalizumab suspension. Dermatology. 2011;222(3):250-255
44. Acharya NR, Hong KC, Lee SM. Ranibizumab for refractory uveitis-related macular edema. Am J Ophthalmol 2009;148:303-309e302
45. Bae JH, Lee CS, Lee SC. Efficacy and safety of intravitreal bevacizumab compared with intravitreal and posterior sub-Tenon triamcinolone acetonide for treatment of uveitic cystoid macular edema. Retina. 2011;31(1):111-118
46. Cordero Coma M, Sobrin L, Onal S, et al. Intravitreal bevacizumab for treatment of uveitic macular edema Ophthalmology. 2007;114:1574-1579 e1571
47. Mackensen F, Heinz C, Becker MD, Heiligenhaus A. Intravitreal bevacizumab (Avastin) as a treatment for refractory macular edema in patients with uveitis: a pilot study. Retina. 2008;28:41-45
48. Cervantes-Castaneda RA, Giuliari GP, Gallagher MJ, et al. Intravitreal bevacizumab in refractory uveitic macular edema: one-year follow-up. Eur J Ophthalmol. 2009;19:622-629
49. Farvardin M, Afarid M, Mehryar M, Hosseini H. Intravitreal infliximab for the treatment of sight-threatening chronic noninfectious uveitis. Retina. 2010;30(9):1530-1535
50. Androudi S, Tsironi E, Kalogeropoulos C, et al. Intravitreal adalimumab for refractory uveitis-related macular edema. Ophthalmology. 2010;117(8):1612-1616
51. Pulido JS, Pulido JE, Michet CJ, Vile RG. More questions than answers: a call for a moratorium on the use of intravitreal infliximab outside of a well-designed trial. Retina. 2010;30(1):1-5
52. Mansour AM, Arevalo JF, Ziemssen F, et al. Long-term visual outcomes of intravitreal bevacizumab in inflammatory ocular neovascularization. Am J Ophthalmol. 2009;148:310-316e312
53. Doctor PP, Bhat P, Sayed R, Foster CS. Intravitreal bevacizumab for uveitic choroidal neovascularization. Ocul Immunol Inflamm. 2009;17:118-126
54. Tran TH, Fardeau C, Terrada C, et al. Intravitreal bevacizumab for refractory choroidal neovascularization (CNV) secondary to uveitis. Graefes Arch Clin Exp Ophthalmol. 2008;246:1685-1692
55. Kurup S, Lew J, Byrnes G, et al. Therapeutic efficacy of intravitreal bevacizumab on posterior uveitis complicated by neovascularization. Acta Ophthalmol. 2009;87:349-352
56. Wu L, Evans T, Saravia M, et al. Intravitreal bevacizumab for choroidal neovascularization secondary to Vogt- Koyanagi-Harada syndrome. Jpn J Ophthalmol. 2009;53:57-60
57. Fine HF, Zhitomirsky I, Freund KB, et al. Bevacizumab (Avastin) and ranibizumab (Lucentis) for choroidal neovascularization in multifocal choroiditis. Retina. 2009;29:8-12.